FDA Clears Welireg-Lenvima Combo for Kidney Cancer

FDA approved belzutifan (Welireg) in combination with lenvatinib (Lenvima) on 24 September 2026 for adults with advanced clear-cell renal cell carcinoma who have progressed after a PD-1 or PD-L1 inhibitor — the first approved regimen pairing a HIF-2α inhibitor with a multitargeted TKI in this post-immunotherapy setting. The approval comes with a nuance regulatory and medical affairs teams will need to manage carefully: the trial that supports it hit its progression-free survival endpoint cleanly, but its overall survival analysis did not reach statistical significance.

Why this approval is different from a typical combination clearance

Belzutifan is already approved as monotherapy for certain von Hippel-Lindau-associated tumors and, since 2023, for previously treated advanced ccRCC. Lenvatinib is a familiar multitargeted tyrosine kinase inhibitor with a long track record in renal and thyroid cancers, typically paired with a checkpoint inhibitor in earlier lines of therapy. What is new here is the specific combination and the specific setting: patients whose disease has already progressed on a checkpoint inhibitor, where oncologists have historically reached for a TKI alone or a TKI paired with a different mechanism. Merck and Eisai's own framing, echoed by both companies' press materials, is that HIF-2α inhibition and VEGFR-pathway blockade attack the tumor through genuinely distinct pathways, which is the scientific rationale for pairing them rather than simply substituting one TKI regimen for another.

The trial data, and the endpoint that did not land

LITESPARK-011 randomized 747 patients with advanced ccRCC 1:1 to belzutifan plus lenvatinib or to cabozantinib alone, all following prior anti-PD-1/PD-L1 therapy. The combination's progression-free survival advantage was large and statistically decisive: a median of 14.8 months against 10.7 months for cabozantinib, a hazard ratio of 0.70 with a tight confidence interval (0.59 to 0.84) and a p-value of 0.00007. Objective response rate favored the combination as well, 53 percent against 40 percent. Those numbers are the approval's foundation, and they are not in dispute across independent oncology trade coverage of the trial.

Overall survival is the harder story. The final analysis showed a hazard ratio of 0.85, a numerical trend toward benefit, but its 95 percent confidence interval (0.70 to 1.03) crosses 1.0 — meaning the trial cannot rule out no survival difference at all. FDA's approval rests on progression-free survival and response rate, which is a well-established regulatory pathway in oncology, but it means the combination's promotional and medical-communications materials need to be precise about what has and has not been shown. A progression-free survival win is real clinical benefit; it is not the same claim as an overall survival win, and label and promotional review teams at both companies will need to keep that distinction airtight as marketing materials go out.

What the companies are saying

“This approval represents real progress for patients and further reinforces the importance of a HIF-2α inhibitor plus TKI combination as a new treatment approach for these patients,” said Dr. M. Catherine Pietanza, vice president of global clinical development at Merck Research Laboratories, per the company's statement. “By bringing together two therapies that each target different pathways, Welireg plus Lenvima is now the first approved regimen of its kind, offering a new treatment option for certain patients with advanced renal cell carcinoma who have progressed after anti-PD-1/PD-L1 therapy.” Eisai's Dr. Corina Dutcus, senior vice president of oncology global clinical development, framed it similarly in the companies' joint announcement: patients facing advanced RCC need options at every stage of a disease whose management only grows more complex over time.

What happens next

• Label and promotional review: materials describing the approval need to keep the progression-free-survival basis and the non-significant overall-survival finding clearly distinct.
• Sequencing questions: oncologists will need guidance on where this combination fits relative to other post-immunotherapy options, including cabozantinib alone, the trial's own comparator.
• International filings: Eisai has separately sought an expanded Lenvima dosing and administration approval in Japan to support use alongside Welireg for RCC that progressed after chemotherapy, a related but distinct regulatory track worth watching for companion approvals abroad.

Frequently asked questions

What did FDA approve on 24 September 2026?

Belzutifan (Welireg, Merck) in combination with lenvatinib (Lenvima, Eisai) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) who have progressed on or after a PD-1 or PD-L1 inhibitor, or within six months of completing adjuvant PD-1 therapy.

What did the pivotal trial show?

LITESPARK-011, a Phase 3 trial of 747 patients, showed median progression-free survival of 14.8 months versus 10.7 months for cabozantinib (HR 0.70, 95% CI 0.59-0.84, p=0.00007), with an objective response rate of 53% versus 40%.

Did the combination improve overall survival?

Not to a statistically significant degree. The final analysis showed a numerical trend (HR 0.85, 95% CI 0.70-1.03) that did not reach statistical significance; FDA's approval rests on progression-free survival and response rate.

What is the dosing regimen?

Belzutifan 120 mg orally once daily plus lenvatinib 20 mg orally once daily, continued until disease progression or unacceptable toxicity.